Drugs / Hepa-B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT03627507 | Jul 2018 → May 2019 | hepatitis B virus infection | International Centre for Diarrhoeal Disease Research, Bangladesh | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT02759991 Comparator | Oct 2017 → Sep 2019 | hepatitis E virus infection | Norwegian Institute of Public Health | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hepa- B | “Incepta will manufacture a locally produced Hepatitis B vaccine named 'Hepa- B' which contain recombinant Hepatitis B surface antigen obtaine.” NCT03627507 ↗ |
| Modality | Vaccine | “a control vaccine (Hepa-B, a hepatitis B vaccine)” PMID 39030060 ↗ Aug 2024 |
| Route | Intramuscular | “Hepa-B, 1 ml intramuscular injection day 0, 1 month and 6 months.” NCT02759991 ↗ |